IGC Pharma, Inc. (IGC) has a negative trailing P/E of -5.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -18.86%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.0 | 0.07 | 0.63 | 1.34 | - |
| 2017 | -6.5 | 0.11 | 1.64 | 20.78 | - |
| 2018 | -8.8 | 0.61 | 1.94 | 7.13 | - |
| 2019 | -17.5 | -0.17 | 2.13 | 13.97 | - |
| 2020 | -2.6 | -0.05 | 0.73 | 4.75 | - |
| 2021 | -8.5 | -0.81 | 2.29 | 83.65 | - |
| 2022 | -3.2 | -0.07 | 1.99 | 119.49 | - |
| 2023 | -1.6 | 0.06 | 1.20 | 19.59 | - |
| 2024 | -2.2 | 0.00 | 3.83 | 20.82 | - |
| 2025 | -3.1 | 0.05 | 3.45 | 17.16 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.17 | $6.37M | $-2.81M | -44.1% |
| 2017 | $-0.07 | $580.37K | $-1.87M | -321.7% |
| 2018 | $-0.06 | $2.19M | $-1.79M | -81.4% |
| 2019 | $-0.12 | $5.12M | $-4.1M | -80.1% |
| 2020 | $-0.19 | $4.07M | $-8.1M | -198.8% |
| 2021 | $-0.21 | $898K | $-8.81M | -981.2% |
| 2022 | $-0.30 | $397K | $-15.02M | -3782.4% |
| 2023 | $-0.22 | $911K | $-11.51M | -1263% |
| 2024 | $-0.22 | $1.35M | $-13M | -966.5% |
| 2025 | $-0.09 | $1.27M | $-7.12M | -560.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.09 | $-0.09 – $-0.09 | $1.06M | $1.06M – $1.06M | 1 |
| 2027 | $-0.09 | $-0.09 – $-0.09 | $1.1M | $1.1M – $1.1M | 1 |
| 2028 | $-0.09 | $-0.09 – $-0.09 | $1.03M | $1.03M – $1.03M | 1 |
